Investigating ASCL1-driven immunological landscapes in neuroendocrine prostate cancer: a strategy for enhancing immunotherapy efficacy

The University of British Columbia received a $426,154 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective September 1, 2025, through August 31, 2027. The grant supports research investigating ASCL1-driven immunological landscapes in neuroendocrine prostate cancer, with the objective of enhancing immunotherapy efficacy. This research falls within the DHA's broader mission to transform healthcare for service members and the American public through innovative biomedical research addressing critical health challenges relevant to military personnel.

The research project will be conducted at The University of British Columbia's Research Services division in Ottawa, Ontario, and represents a translational research initiative focused on understanding the immunological mechanisms underlying neuroendocrine prostate cancer. The award supports hypothesis-driven research designed to develop novel therapeutic strategies and potentially improve treatment outcomes for this aggressive cancer subtype. As a two-year project grant, this award exemplifies the DHA's investment in cancer immunotherapy research through its congressionally-directed medical research programs, aligning with the agency's commitment to advancing military-relevant medical research through partnerships with leading international academic institutions.